Stay updated on BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Sign up to get notified when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.

Latest updates to the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe completed Phase 1 BGB-A317 study record is now displayed, including its eligibility criteria, study design, outcome measures, results-related information, and study documents.SummaryDifference68%

- Check20 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0 while the study record remains inaccessible behind a 403 Forbidden page.SummaryDifference0.2%

- Check27 days agoChange DetectedA sitewide NIH banner announces updates about the agency’s website transition and notes that NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision indicator changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now renders a 403 Forbidden error page, complete with a DOCTYPE and a 403 header, and a Home link, signaling the study record is inaccessible; the footer shows a revision version and previously visible documents/details are no longer displayed on the page.SummaryDifference19%

Stay in the know with updates to BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Enter your email address, and we'll notify you when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.